Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

2026 & BEYOND MASTER PLAN

Introduction

LPBI Group: A Rare, Production-Ready Intelligence Platform for Domain-Aware AI in Health

The transformation of life sciences by artificial intelligence is no longer a future possibility — it is an active, accelerating reality. Major pharmaceutical companies, hyperscalers, and frontier AI laboratories are rapidly scaling AI systems across drug discovery, clinical development, manufacturing, and commercial operations. Yet, as these systems grow in capability and ambition, a critical gap has become increasingly clear: most platforms still lack access to high-quality, causally structured, and domain-specific biomedical intelligence at scale.

LPBI Group was built to close this gap.

Over 14 years of continuous operation, LPBI Group has developed a unique and defensible combination of assets that few organizations in the world can match:

• A 9 GB private multimodal corpus — one of the largest proprietary, expert-curated trainable datasets in Life Sciences, Pharmaceuticals, Medicine, and Healthcare — consisting entirely of content written by advanced-degree professionals (physicians, scientists, and clinical experts).
• A 17-part Composition of Methods (COM) Tool Factory, a proprietary suite of methodologies and systems invented in-house between 2012 and 2026. This includes AJAUS (COM Part 14), a governed autonomous multi-agent updating and orchestration system, and the Rosetta Stone Ontology (COM Part 15), a structured translational framework for mechanism-of-action and clinical reasoning.
• Deep domain expertise embedded in both the data and the methods, reflecting 14 years of disciplined curation and the Founder’s long-standing work in Algorithm-based Decision Support Systems and Expert Systems since 1976.

This combination — proprietary trainable data at scale + a comprehensive, purpose-built methodology framework + deep domain knowledge — positions LPBI Group as a rare upstream intelligence layer for the next generation of AI systems in healthcare.

Unlike most available datasets, LPBI’s corpus was not assembled from public sources or general web scraping. It was deliberately and systematically curated by domain experts to support high-stakes scientific and clinical reasoning. This makes it particularly valuable for organizations seeking to move beyond generic model performance toward reliable, domain-aware, and regulator-ready AI applications.

Expert leadership in the clinical interpretation of scientific findings has produced a curated corpus of approximately 6,300 articles — read by more than 2.5 million e-readers — along with 48 e-books generating over 152,000 page downloads, establishing a level of sustained, high-quality domain-specific output rarely achieved in the life sciences.

LPBI Group’s strategic objective is the Transfer of Ownership of this integrated IP ecosystem — the multimodal corpus, the full COM Tool Factory, and the associated domain expertise — to a partner with the scale, infrastructure, and vision to deploy it at its full potential. Whether through collaboration with frontier AI laboratories, integration into hyperscaler platforms, or strategic partnership with leading pharmaceutical and biotechnology companies, LPBI’s assets are designed to materially strengthen the performance, trustworthiness, and scientific depth of advanced AI systems in Health.

The following pages present LPBI Group’s integrated value proposition in greater detail.

Public Pages (Open Access)

• 1. Founder’s Vision

• 2. LPBI Group’s History

• 3. 2.0 LPBI – 2021-2026 Reality

• 4. Journal PharmaceuticalIntelligence.com

• 5. BioMed e-Series

• 6. Portfolio of IP Assets

• 7. Knowledge PORTALS System (KPS)

• 8. TOOL FACTORY, Composition of Methods (COM), IP Asset Class IV

• 9. Total Valuation & Waterfall

• 10. Joint Articles & Proof Points

• 11. Future Scenarios & Exit Path

• 12. Investor Relations & Next Steps

Password-Protected Strategic Customized Decks (Confidential – For approved investors, strategic partners, board members, and authorized LPBI Group Business Development professionals only)

For Access to Strategic Customized Decks, click on

• Access to Password-Protected Strategic Customized Decks

 

This page has the following sub pages.

• 1. Founder’s Vision
• 2. LPBI Group’s History
• 3. 2.0 LPBI – 2021-2026 Reality
• 4. Journal PharmaceuticalIntelligence.com
• 5. BioMed e-Series
• 6. Portfolio of IP Assets
• 7. Knowledge PORTALS System (KPS)
• 8. TOOL FACTORY, Composition of Methods (COM), IP Asset Class IV
• 9. Total Valuation & Waterfall
• 10. Joint Articles & Proof Points
• 11. Future Scenarios & Exit Path
• 12. Investor Relations & Next Steps